

ERN-EUROBLOODNET

EUROPEAN REFERENCE NETWORK ON RARE HEMATOLOGICAL DISEASES

LIST OF CPGs AND CDMTs

2. CLINICAL CARE

2.1.1 The ERN has developed or adapted (from other sources) and disseminated clinical guidelines and other types of clinical decision-making tools in collaboration with the HCPs

Supporting Document 14. List of clinical guidelines and clinical decision-making tools disseminated

2.1.2 The ERN has implemented guidelines and/or protocols to support transition and continuity of care from childhood, through adolescence, and into adulthood, where applicable.

Supporting Document 15 List of guidelines/protocols/best practices to support transition and continuity of care

REPOSITORY OF CPGs AND CDMTs

A number of international Clinical Practice Guidelines (CPG) and other Clinical Decision Making Tools (CDMT) have been published so far on prevention, diagnosis, and clinical care in RHD. However, no central repository compiling both oncological and non-oncological disorders CPGs and CDMTs was available at the time of ERN establishment.

ERN-EuroBloodNet aimed to create a comprehensive repository of CPG and CDMT classified by quality domains and to identify gaps for promoting the creation of new ones on areas where they are lacking.

An initial list of 116 CPG and other CDMT was compiled with the feedback from subnetwork coordinators and members.

The methodology for their classification on Quality Domains was defined, including:

- Scope and Purpose (Prevention, Diagnosis, Treatment, Transition to adulthood)
- Patient involvement
- Rigour of Development:
 - A Evidence and consensus based
 - B Consensus based
 - C Expert opinion

Full methodology description is available at [ERN-EuroBloodNet website Best Practices section](#).

ERN-EuroBloodNet repository of CPG and CDMT adopted by the ERN after assessment on quality domains currently includes a list of 69 RHD CPG and other CDMT being accounted under ERN Monitoring indicator "**6.1 Number of Clinical Practice Guidelines and other types of Clinical Decision Making Tools, adopted for diseases within the scope of the ERN during the reporting period**". The following number of CPGs and other CDMTs have been classified for each subnetwork:

- Red blood cell disorders: 25 (including 11A, 13B and 1C)
- Bone marrow failure: 13 (including 3B and 10C)
- Haemochromatosis and other iron related disorders: 6 (including 4A and 2C)
- Myeloid malignancies: 26 (including 14A, 10B and 2C)

Classification on quality domains of the documents compiled for Bleeding and coagulation and lymphoid subnetworks will be finalized and uploaded on the website during 2023-2024. The following number of CPGs and other CDMTs are under assessment:

- Bleeding-coagulation disorders: 22
- Lymphoid malignancies: 22



Moreover, a [search engine](#) was implemented at the website to allow how to find documents by disease and quality domains defined.

Regarding ERN Monitoring indicator "**6.2: Number of new Clinical Practice Guidelines and other types of Clinical Decision Making Tools (clinical consensus statements or consensus recommendations), written by the ERN**", the following 3 Recommendations have been written by the ERN 2017-2021:

- [Iolascon A et al; SWG of red cell and iron of EHA and EuroBloodNet. Recommendations for diagnosis and treatment of methemoglobinemia. Am J Hematol. 2021 Dec 1;96\(12\):1666-1678.](#)
- [Lobitz S, with the endorsement of EuroBloodNet, the European Reference Network in Rare Haematological Diseases. Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. Br J Haematol. 2018 Nov;183\(4\):648-660.](#)
- [Bianchi P et al with the endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases. Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. Am J Hematol. 2019 Jan;94\(1\):149-161.](#)

LIST OF CLINICAL GUIDELINES AND CLINICAL DECISION-MAKING TOOLS DISSEMINATED

The "List of clinical guidelines and clinical decision-making tools disseminated" includes the 116 CPG and other CDMT compiled for all the RHD, including:

- ERN monitoring indicator 6.2: CPG and CDMT written by the ERN, indicated with 
- CPG and CDMT covering childhood-adulthood transition is indicated with 

	Red Blood Cell defects	Link
1	Guidelines for the diagnosis and management of hereditary spherocytosis – 2011 update	https://www.ncbi.nlm.nih.gov/pubmed/22055020
2	ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders	https://www.ncbi.nlm.nih.gov/pubmed/25790109
3	Standards for the clinical care of children and adults with thalassaemia in the UK	https://ukts.org/resources/national-standards/
4	Recommendations regarding splenectomy in hereditary hemolytic anemias.	https://www.ncbi.nlm.nih.gov/pubmed/28550188
5	Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide	https://www.ncbi.nlm.nih.gov/pubmed/25255924
6	EMQN Best Practice Guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies	https://www.ncbi.nlm.nih.gov/pubmed/25052315
7	Significant haemoglobinopathies: guidelines for screening and diagnosis	https://pubmed.ncbi.nlm.nih.gov/20067565/
8	NHS SCT Handbook for Newborn Laboratories	https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/656094/Antenatal_Laboratory_Handbook.pdf
9	Antenatal Laboratory Handbook SCD and Thalassaemia Screening Programme	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/585126/NHS_SCT_Handbook_for_Newborn_Laboratories.pdf
10	Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014	https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease
11	ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children	https://www.ncbi.nlm.nih.gov/pubmed/20981677
12	Recommended methods for the characterization of red cell pyruvate kinase variants	https://www.ncbi.nlm.nih.gov/pubmed/41566
13	Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.	https://pubmed.ncbi.nlm.nih.gov/24787449/
14	Preterm Neonates: Beyond the Guidelines for Neonatal Hyperbilirubinemia	https://www.ncbi.nlm.nih.gov/pubmed/27235216
15	Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis	https://pubmed.ncbi.nlm.nih.gov/16029446/
16	Prevention and Diagnosis of Haemoglobinopathies: A Short Guide for Health Professionals and Laboratory Scientists (2016)	http://thalassaemia.org.cy/publications/tif-publications/prevention-and-diagnosis-of-haemoglobinopathies-a-short-guide-for-health-professionals-and-laboratory-scientists/
17	Guidelines for the management of non transfusion dependent thalassaemia (NTDT) 2ND edition	https://www.ncbi.nlm.nih.gov/pubmed/24672826
18	A guide for haemoglobinopathy nurse	http://thalassaemia.org.cy/publications/tif-publications/a-guide-for-the-haemoglobinopathy-nurse-2013/

	Red Blood Cell defects	Link
19	Prevention of Thalassaemias and other Haemoglobin Disorders, Vol 1, 2nd Edition (2013)	https://www.ncbi.nlm.nih.gov/pubmed/24672827
20	A Short Guide to the Management of Transfusion Dependent Thalassaemia	http://thalassaemia.org.cy/publications/tif-publications/a-short-guide-to-the-management-of-transfusion-dependent-thalassaemia/
21	Emergency Management of Thalassaemia (2012)	https://www.ncbi.nlm.nih.gov/pubmed/24672825
22	Guidelines for the Management of Transfusion Dependent Thalassaemia, 3rd Edition (2014)	https://www.ncbi.nlm.nih.gov/pubmed/25610943
23	Prevention of Thalassaemias and Other Haemoglobin Disorders, Vol. 2: Laboratory Protocols (2012)	https://www.ncbi.nlm.nih.gov/pubmed/24672828
24	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. (2019)	https://www.ncbi.nlm.nih.gov/pubmed/30358897
25	Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference	https://pubmed.ncbi.nlm.nih.gov/30334577/
26	Recommendations for diagnosis and treatment of methemoglobinemia	https://pubmed.ncbi.nlm.nih.gov/34467556/

	Bone Marrow Failures	Link
1	Diagnosis and management of congenital dyserythropoietic anemias	https://www.ncbi.nlm.nih.gov/pubmed/26653117
2	Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference	https://www.ncbi.nlm.nih.gov/pubmed/18671700
3	How I treat Diamond-Blackfan anemia	https://pubmed.ncbi.nlm.nih.gov/20651069/
4	Guidelines for the diagnosis and management of adult aplastic anaemia	https://www.ncbi.nlm.nih.gov/pubmed/26568159
5	How I manage patients with Fanconi anaemia	https://www.ncbi.nlm.nih.gov/pubmed/28474441
6	How I treat MDS and AML in Fanconi anemia	https://pubmed.ncbi.nlm.nih.gov/27020090/
7	Paroxysmal nocturnal hemoglobinuria	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215311/
8	Paroxysmal Nocturnal Hemoglobinuria	https://www.intechopen.com/books/anemia/paroxysmal-nocturnal-hemoglobinuria
9	Haematopoietic and immune defects associated with GATA2 mutation	https://www.ncbi.nlm.nih.gov/pubmed/25707267
10	GATA2 deficiency and related myeloid neoplasms	https://www.ncbi.nlm.nih.gov/pubmed/28637621
11	Transplantation for bone marrow failure: current issues	https://www.ncbi.nlm.nih.gov/pubmed/27913467
12	Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes	https://www.ncbi.nlm.nih.gov/pubmed/26052913
13	Recommendations regarding splenectomy in hereditary hemolytic anemias.	https://www.ncbi.nlm.nih.gov/pubmed/28550188

	Haemochromatosis and iron related disorders	Link
1	The quality of hereditary haemochromatosis guidelines: a comparative analysis	https://www.ncbi.nlm.nih.gov/pubmed/25441394
2	European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis.	https://www.ncbi.nlm.nih.gov/pubmed/20471131
3	American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases	https://www.ncbi.nlm.nih.gov/pubmed/21452290
4	EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH)	https://www.ncbi.nlm.nih.gov/pubmed/26153218
5	Reassessing the Safety Concerns of Utilizing Blood Donations from Patients with Hemochromatosis. Hepatology	https://www.ncbi.nlm.nih.gov/pubmed/28902419
6	Molecular diagnosis of hemochromatosis	https://www.ncbi.nlm.nih.gov/pubmed/23530886
7	Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis	https://www.ncbi.nlm.nih.gov/pubmed/24665134
8	Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype	https://www.ncbi.nlm.nih.gov/pubmed/29589198
9	Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis.	https://www.ncbi.nlm.nih.gov/pubmed/27733158



	Bleeding-coagulation disorders	Link
1	WFH Guidelines: Guidelines for the management of haemophilia	http://www.haemophiliacentral.org/Guidelines.aspx
2	Guideline on the management of haemophilia in the fetus and neonate	http://www.haemophiliacentral.org/Guidelines.aspx
3	Practice Guidelines for the Molecular Diagnosis of Haemophilia A	http://www.haemophiliacentral.org/Guidelines.aspx
4	Practice Guidelines for the Molecular Diagnosis of Haemophilia B	http://www.haemophiliacentral.org/Guidelines.aspx
5	A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A	http://www.haemophiliacentral.org/Guidelines.aspx
6	Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology	http://www.haemophiliacentral.org/Guidelines.aspx
7	A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO	http://www.haemophiliacentral.org/Guidelines.aspx
8	The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network	http://www.haemophiliacentral.org/Guidelines.aspx
9	Management of von Willebrand's disease: a guideline from the UK Haemophilia Centre Doctors' Organisation	http://www.haemophiliacentral.org/Guidelines.aspx
10	The diagnosis of von Willebrand's disease: a guideline from the UK Haemophilia Centre Doctors' Organisation	http://www.haemophiliacentral.org/Guidelines.aspx
11	Emergency and out of hours care for patients with bleeding disorders – Standards of care for assessment and treatment	http://www.haemophiliacentral.org/Guidelines.aspx
12	A framework for genetic service provision for haemophilia and other inherited bleeding disorders	http://www.haemophiliacentral.org/Guidelines.aspx
13	UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011.	http://www.haemophiliacentral.org/Guidelines.aspx
14	Guideline on the diagnosis and management of chronic liver disease in haemophilia	http://www.haemophiliacentral.org/Guidelines.aspx
15	The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation	http://www.haemophiliacentral.org/Guidelines.aspx
16	The obstetric and gynaecological management of women with inherited bleeding disorders-review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization	http://www.haemophiliacentral.org/Guidelines.aspx

	Bleeding-coagulation disorders	Link
17	The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation	http://www.haemophiliacentral.org/Guidelines.aspx
18	Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline.	https://www.ncbi.nlm.nih.gov/pubmed/28370924
19	Primary prophylaxis in haemophilia care: Guideline update 2016	https://www.ncbi.nlm.nih.gov/pubmed/28363466
20	European principles of inhibitor management in patients with haemophilia.	https://www.ncbi.nlm.nih.gov/pubmed/29703220
21	Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.	https://www.ncbi.nlm.nih.gov/pubmed/22624596
22	Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan	https://www.ncbi.nlm.nih.gov/pubmed/28550351

	Lymphoid malignancies	Link
1	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)	https://www.ncbi.nlm.nih.gov/pubmed/23175624
2	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma	https://www.ncbi.nlm.nih.gov/pubmed/?term=ESMO+Consensus+conferences%3A+guidelines+on+malignant+lymphoma+part+2
3	Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up	https://www.ncbi.nlm.nih.gov/pubmed/?term=Hairy+cell+leukaemia%3A+ESMO+Clinical+Practice+Guidelines+for+diagnosis%2C+treatment+and+follow-up
4	AL amyloidosis: from molecular mechanisms to targeted therapies	https://www.ncbi.nlm.nih.gov/pubmed/29222231
5	Update on nodal and splenic marginal zone lymphoma	https://www.ncbi.nlm.nih.gov/pubmed/29222281
6	Acute lymphoblastic leukemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up	https://www.ncbi.nlm.nih.gov/pubmed/?term=Acute+lymphoblastic+leukemia+in+adult+patients%3A+ESMO+clinical+practice+guidelines+for+diagnosis%2C+treatment+and+follow-up
7	Acute lymphoblastic leukemia: Version 2.2015	https://www.ncbi.nlm.nih.gov/pubmed/26483064
8	Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up	https://www.ncbi.nlm.nih.gov/pubmed/24078657
9	Guidelines on the management of AL amyloidosis	https://www.ncbi.nlm.nih.gov/pubmed/25303672
10	Hodgkin's lymphoma: ESMO clinical practice guidelines on diagnosis, treatment and follow up	https://www.ncbi.nlm.nih.gov/pubmed/25185243
11	Hodgkin lymphoma, Version 1.2017	https://www.ncbi.nlm.nih.gov/pubmed/28476741
12	Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608228/
13	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome	https://www.ncbi.nlm.nih.gov/pubmed/?term=Guideline+for+the+diagnosis%2C+treatment+and+response+criteria+for+Bing-Neel+syndrome
14	Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop	https://www.ncbi.nlm.nih.gov/pubmed/23150997
15	Guidelines for Diagnosis, Indications for Treatment, Response Assessment and Supportive Management of Chronic Lymphocytic Leukemia	https://www.ncbi.nlm.nih.gov/pubmed/?term=Guidelines+for+Diagnosis%2C+Indications+for+Treatment%2C+Response+Assessment+and+Supportive+Management+of+Chronic+Lymphocytic+Leukemia
16	Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel	https://www.ncbi.nlm.nih.gov/pubmed?term=Investigation%20and%20management%20of%20IgM%20and%20Waldenstrom-associated%20peripheral%20neuropathies:%20recommendations%20from%20the%20IWWM-8%20consensus%20panel[all]&cmd=correctspelling

	Lymphoid malignancies	Link
17	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia	https://www.ncbi.nlm.nih.gov/pubmed/?term=Treatment+recommendations+from+the+Eighth+International+Workshop+on+Waldenstr%C3%B6m%E2%80%99s+Macroglobulinemia
18	A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.	https://www.ncbi.nlm.nih.gov/pubmed/26639181
19	Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations.	https://www.ncbi.nlm.nih.gov/pubmed/28439111
20	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.	https://www.ncbi.nlm.nih.gov/pubmed/29997221
21	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project	https://www.ncbi.nlm.nih.gov/pubmed/29024461
22	ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.	https://www.ncbi.nlm.nih.gov/pubmed/29467486

	Myeloid malignancies	Link
1	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet	https://www.ncbi.nlm.nih.gov/pubmed/23980065
2	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.	https://www.ncbi.nlm.nih.gov/pubmed?term=27895058
3	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.	https://www.ncbi.nlm.nih.gov/pubmed/28982745
4	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet	https://www.ncbi.nlm.nih.gov/pubmed/18812465
5	Diagnosis and management of mastocytosis: an emerging challenge in applied hematology	https://www.ncbi.nlm.nih.gov/pubmed/26637707
6	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.	https://www.ncbi.nlm.nih.gov/pubmed/28096091
7	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.	https://www.ncbi.nlm.nih.gov/pubmed/29330221
8	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.	https://www.ncbi.nlm.nih.gov/pubmed/23838352
9	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.	https://www.ncbi.nlm.nih.gov/pubmed/23591792
10	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.	https://www.ncbi.nlm.nih.gov/pubmed/21205761
11	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.	https://www.ncbi.nlm.nih.gov/pubmed/25624319
12	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.	https://www.ncbi.nlm.nih.gov/pubmed/23803709
13	European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia	https://www.ncbi.nlm.nih.gov/pubmed/27121688

	Myeloid malignancies	Link
14	Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations	https://www.ncbi.nlm.nih.gov/pubmed/27740634
15	Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study	https://www.ncbi.nlm.nih.gov/pubmed/26922887
16	The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.	https://www.ncbi.nlm.nih.gov/pubmed/27892949
17	Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)	https://www.ncbi.nlm.nih.gov/pubmed/27599653
18	ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients	https://www.ncbi.nlm.nih.gov/pubmed/27550993
19	ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.	https://www.ncbi.nlm.nih.gov/pubmed/27550992
20	ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients	https://www.ncbi.nlm.nih.gov/pubmed/27550991
21	Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients	https://www.ncbi.nlm.nih.gov/pubmed/27550990
22	Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.	https://www.ncbi.nlm.nih.gov/pubmed/27365460
23	ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients	https://www.ncbi.nlm.nih.gov/pubmed/29190347
24	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines	https://www.ncbi.nlm.nih.gov/pubmed/29079323
25	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients	https://www.ncbi.nlm.nih.gov/pubmed/28011902
26	Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.	https://www.ncbi.nlm.nih.gov/pubmed/30404811



European
Reference
Network

https://ec.europa.eu/health/ern_en



European
Reference
Network

for rare or low prevalence
complex diseases

 **Network**
Hematological
Diseases (ERN EuroBloodNet)

www.eurobloodnet.eu

Disclaimer:



Co-funded by
the European Union

The content of this deliverable represents the views of the authors only and it is their sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

As of the 1st of April 2021 the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ceased to exist. The portfolio of actions managed by CHAFEA under the 3rd HP was transferred to the Health and Digital Executive Agency (HaDEA).